​

Genmab (GMAB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GMAB Stock Forecast

Genmab stock forecast is as follows: an average price target of $43.50 (represents a 114.18% upside from GMAB’s last price of $20.31) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

GMAB Price Target

The average price target for Genmab (GMAB) is $43.50 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $31.00. This represents a potential 114.18% upside from GMAB's last price of $20.31.

GMAB Analyst Ratings

Buy

According to 11 Wall Street analysts, Genmab's rating consensus is 'Buy'. The analyst rating breakdown for GMAB stock is 0 'Strong Buy' (0.00%), 8 'Buy' (72.73%), 3 'Hold' (27.27%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Genmab Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 04, 2024Vikram PurohitMorgan Stanley$31.00$27.4113.10%52.63%
Aug 09, 2024Etzer DaroutBMO Capital$46.00$27.0769.93%126.49%
Jun 27, 2024Kaveri PohlmanBTIG$47.00$25.6783.09%131.41%
Jun 27, 2024Raghuram SelvarajuH.C. Wainwright$50.00$25.7194.48%146.18%
Jun 04, 2024Asthika GoonewardeneTruist Financial$53.00$28.8383.84%160.96%
Feb 23, 2024Etzer DaroutBMO Capital$48.00$29.1664.61%136.34%
Feb 06, 2023Leerink Partners$36.00$38.26-5.91%77.25%
Nov 28, 2022Matthew HarrisonMorgan Stanley$34.00$44.83-24.16%67.41%
May 02, 2022Cowen & Co.$38.00$34.918.85%87.10%

The latest Genmab stock forecast, released on Sep 04, 2024 by Vikram Purohit from Morgan Stanley, set a price target of $31.00, which represents a 13.10% increase from the stock price at the time of the forecast ($27.41), and a 52.63% increase from GMAB last price ($20.31).

Genmab Price Target by Period

1M3M12M
# Anlaysts--6
Avg Price Target--$45.83
Last Closing Price$20.31$20.31$20.31
Upside/Downside-100.00%-100.00%125.65%

In the current month, the average price target of Genmab stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Genmab's last price of $20.31. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2024H.C. WainwrightBuyBuyHold
Oct 11, 2024Cowen & Co.HoldHoldHold
Sep 20, 2024Johnson RiceBuyBuyHold
Sep 13, 2024H.C. WainwrightBuyBuyHold
Sep 09, 2024Morgan StanleyBuyBuyHold
Aug 20, 2024H.C. WainwrightBuyBuyHold
Aug 09, 2024Cowen & Co.HoldHoldHold
Aug 09, 2024BMO CapitalOutperformOutperformHold
Aug 01, 2024BTIGUnderperformUnderperformHold
Jul 19, 2024H.C. WainwrightBuyBuyHold
Jul 15, 2024RBC CapitalOutperformUpgrade
Jul 10, 2024BarclaysOverweightOverweightHold
Jun 27, 2024BTIGBuyBuyHold
Jun 27, 2024H.C. WainwrightBuyBuyHold
Jun 20, 2024Morgan StanleyUnderperformUnderperformHold
Jun 20, 2024Truist FinancialBuyBuyHold
May 20, 2024Morgan StanleyBuyBuyHold
May 20, 2024H.C. WainwrightUnderperformUnderperformHold
May 03, 2024CitigroupPositivePositiveHold
Apr 30, 2024Truist FinancialBuyBuyHold
Feb 23, 2024BMO CapitalOutperformUpgrade
Feb 20, 2024H.C. WainwrightBuyBuyHold
Jan 29, 2024Morgan StanleyBuyBuyHold
Feb 06, 2023SVB LeerinkMarket PerformMarket PerformHold
Nov 14, 2022William BlairMarket PerformInitialise
Nov 14, 2022Morgan StanleyUnderweightUnderweightHold
Jul 19, 2022BarclaysOverweightOverweightHold
May 02, 2022Cowen & Co.Market PerformInitialise

Genmab's last stock rating was published by H.C. Wainwright on Oct 16, 2024. The company gave GMAB a "Buy" rating, the same as its previous rate.

Genmab Financial Forecast

Genmab Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue---------------$2.85B$5.23B$4.09B$3.16B$2.12B$2.62B$2.31B$1.97B$1.58B$2.04B$1.72B$5.45B$892.00M$2.96B$1.04B
Avg Forecast$7.80B$7.52B$7.32B$6.23B$6.54B$6.30B$5.96B$4.69B$6.15B$5.53B$5.08B$3.97B$4.55B$4.55B$4.10B$2.77B$4.71B$3.61B$2.93B$2.02B$2.55B$2.17B$1.70B$1.39B$1.77B$1.51B$5.72B$890.63M$2.67B$933.08M
High Forecast$8.27B$7.97B$7.75B$6.60B$6.93B$6.67B$6.31B$5.04B$6.51B$5.55B$5.08B$3.97B$4.78B$5.03B$4.35B$2.93B$4.99B$3.61B$2.93B$2.02B$2.55B$2.17B$1.70B$1.39B$1.77B$1.51B$5.72B$890.63M$2.67B$933.08M
Low Forecast$7.33B$7.07B$6.88B$5.86B$6.15B$5.92B$5.60B$4.35B$5.91B$5.50B$5.08B$3.97B$4.27B$4.34B$3.86B$2.60B$4.43B$3.61B$2.93B$2.02B$2.55B$2.17B$1.70B$1.39B$1.77B$1.51B$5.72B$890.63M$2.67B$933.08M
# Analysts111111128422597437434744464474
Surprise %---------------1.03%1.11%1.13%1.08%1.05%1.03%1.06%1.16%1.13%1.15%1.14%0.95%1.00%1.11%1.11%

Genmab's average Quarter revenue forecast for Jun 23 based on 7 analysts is $4.10B, with a low forecast of $3.86B, and a high forecast of $4.35B. GMAB's average Quarter revenue forecast represents a 43.82% increase compared to the company's last Quarter revenue of $2.85B (Mar 23).

Genmab EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111128422597437434744464474
EBITDA---------------$629.00M$2.81B$2.03B$2.69B$550.00M$969.00M$1.40B$852.00M$1.43B$-128.00M$1.39B$4.55B$356.00M$1.96B$699.28M
Avg Forecast$3.68B$3.54B$3.45B$2.94B$3.08B$2.97B$2.81B$2.21B$2.90B$2.60B$2.39B$1.87B$2.14B$2.14B$1.93B$1.30B$4.34B$1.76B$1.43B$986.53M$1.25B$1.06B$828.01M$681.24M$865.63M$735.82M$2.79B$434.94M$1.30B$455.67M
High Forecast$3.89B$3.75B$3.65B$3.11B$3.27B$3.14B$2.97B$2.38B$3.06B$2.62B$2.39B$1.87B$2.25B$2.37B$2.05B$1.38B$5.20B$1.76B$1.43B$986.53M$1.25B$1.06B$828.01M$681.24M$865.63M$735.82M$2.79B$434.94M$1.30B$455.67M
Low Forecast$3.46B$3.33B$3.24B$2.76B$2.90B$2.79B$2.64B$2.05B$2.78B$2.59B$2.39B$1.87B$2.01B$2.04B$1.82B$1.23B$3.47B$1.76B$1.43B$986.53M$1.25B$1.06B$828.01M$681.24M$865.63M$735.82M$2.79B$434.94M$1.30B$455.67M
Surprise %---------------0.48%0.65%1.15%1.88%0.56%0.78%1.32%1.03%2.09%-0.15%1.89%1.63%0.82%1.51%1.53%

7 analysts predict GMAB's average Quarter EBITDA for Jun 23 to be $1.93B, with a high of $2.05B and a low of $1.82B. This is 207.46% upper than Genmab's previous annual EBITDA (Mar 23) of $629.00M.

Genmab Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111128422597437434744464474
Net Income---------------$226.00M$584.00M$2.58B$1.89B$465.00M$716.00M$890.00M$306.00M$1.10B$581.00M$530.00M$3.38B$269.00M$1.47B$537.05M
Avg Forecast$3.35B$2.98B$2.73B$1.87B$1.79B$1.61B$1.41B$657.61M$1.57B$1.34B$1.40B$6.61B$1.38B$1.51B$1.28B$5.93B$3.20B$1.08B$895.75M$5.29B$635.73M$546.69M$294.16M$5.73B$483.58M$392.72M$3.50B$1.78B$1.44B$242.06M
High Forecast$3.61B$3.21B$2.95B$2.02B$1.93B$1.74B$1.52B$708.59M$2.21B$1.34B$1.40B$7.93B$2.11B$1.88B$1.38B$7.11B$3.85B$1.08B$895.75M$6.34B$635.73M$546.69M$294.16M$6.87B$483.58M$392.72M$3.50B$2.14B$1.44B$242.06M
Low Forecast$3.08B$2.75B$2.52B$1.73B$1.65B$1.49B$1.30B$606.32M$1.19B$1.33B$1.40B$5.29B$851.09M$1.34B$1.18B$4.74B$2.56B$1.08B$895.75M$4.23B$635.73M$546.69M$294.16M$4.58B$483.58M$392.72M$3.50B$1.43B$1.44B$242.06M
Surprise %---------------0.04%0.18%2.38%2.11%0.09%1.13%1.63%1.04%0.19%1.20%1.35%0.97%0.15%1.03%2.22%

Genmab's average Quarter net income forecast for Jun 23 is $1.28B, with a range of $1.18B to $1.38B. GMAB's average Quarter net income forecast represents a 468.14% increase compared to the company's last Quarter net income of $226.00M (Mar 23).

Genmab SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111128422597437434744464474
SG&A---------------$676.00M$921.00M$670.00M$633.00M$452.00M$512.00M$306.00M$264.00M$201.00M$231.00M$145.00M$179.00M$106.00M$116.55M$81.22M
Avg Forecast$1.04B$998.38M$971.35M$827.14M$868.43M$836.04M$791.02M$623.35M$816.11M$733.84M$674.57M$527.30M$603.90M$603.68M$544.98M$367.68M$2.29B$472.92M$384.28M$264.98M$334.72M$285.25M$222.40M$1.05B$232.50M$197.64M$750.63M$702.20M$349.75M$122.39M
High Forecast$1.10B$1.06B$1.03B$876.46M$920.21M$885.89M$838.19M$669.31M$863.68M$737.26M$674.57M$527.30M$635.30M$667.69M$577.48M$389.61M$2.75B$472.92M$384.28M$264.98M$334.72M$285.25M$222.40M$1.26B$232.50M$197.64M$750.63M$842.64M$349.75M$122.39M
Low Forecast$973.68M$938.49M$913.07M$777.51M$816.33M$785.88M$743.56M$577.38M$784.15M$730.42M$674.57M$527.30M$566.75M$575.98M$512.29M$345.62M$1.83B$472.92M$384.28M$264.98M$334.72M$285.25M$222.40M$839.95M$232.50M$197.64M$750.63M$561.76M$349.75M$122.39M
Surprise %---------------1.84%0.40%1.42%1.65%1.71%1.53%1.07%1.19%0.19%0.99%0.73%0.24%0.15%0.33%0.66%

Genmab's average Quarter SG&A projection for Jun 23 is $544.98M, based on 7 Wall Street analysts, with a range of $512.29M to $577.48M. The forecast indicates a -19.38% fall compared to GMAB last annual SG&A of $676.00M (Mar 23).

Genmab EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111128422597437434744464474
EPS---------------$0.35$0.89$3.96$2.89$0.71$1.09$1.36$0.47$1.68$0.89$0.81$5.19$0.41$2.30$0.84
Avg Forecast$5.16$4.59$4.21$2.88$2.76$2.48$2.18$1.01$2.42$2.06$2.16$1.29$2.12$2.33$1.98$0.64$2.34$1.67$1.38$0.53$0.98$0.84$0.45$0.29$0.75$0.61$5.39$0.13$2.21$0.37
High Forecast$5.56$4.95$4.54$3.11$2.97$2.68$2.35$1.09$3.40$2.07$2.16$1.34$3.25$2.90$2.13$0.69$2.52$1.67$1.38$0.53$0.98$0.84$0.45$0.29$0.75$0.61$5.39$0.13$2.21$0.37
Low Forecast$4.75$4.24$3.89$2.66$2.54$2.29$2.01$0.93$1.83$2.05$2.16$1.24$1.31$2.06$1.82$0.59$2.15$1.67$1.38$0.53$0.98$0.84$0.45$0.29$0.75$0.61$5.39$0.13$2.21$0.37
Surprise %---------------0.55%0.38%2.37%2.09%1.33%1.11%1.62%1.03%5.76%1.20%1.34%0.96%3.27%1.04%2.25%

According to 7 Wall Street analysts, Genmab's projected average Quarter EPS for Jun 23 is $1.98, with a low estimate of $1.82 and a high estimate of $2.13. This represents a 465.40% increase compared to GMAB previous annual EPS of $0.35 (Mar 23).

Genmab Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
LEGNLegend Biotech$34.68$89.60158.36%Buy
GMABGenmab$20.03$43.50117.17%Buy
ALECAlector$1.89$4.00111.64%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
CYTKCytokinetics$47.78$90.0088.36%Buy
PCVXVaxcyte$89.86$148.8065.59%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy
ASNDAscendis Pharma$140.30$211.1450.49%Buy
BGNEBeiGene$179.06$267.3349.30%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
TVTXTravere Therapeutics$17.14$21.7526.90%Buy

GMAB Forecast FAQ

Is Genmab a good buy?

Yes, according to 11 Wall Street analysts, Genmab (GMAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 72.73% of GMAB's total ratings.

What is GMAB's price target?

Genmab (GMAB) average price target is $43.5 with a range of $31 to $50, implying a 114.18% from its last price of $20.31. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Genmab stock go up soon?

According to Wall Street analysts' prediction for GMAB stock, the company can go up by 114.18% (from the last price of $20.31 to the average price target of $43.5), up by 146.18% based on the highest stock price target, and up by 52.63% based on the lowest stock price target.

Can Genmab stock reach $30?

GMAB's average twelve months analyst stock price target of $43.5 supports the claim that Genmab can reach $30 in the near future.

What are Genmab's analysts' financial forecasts?

Genmab's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $23.49B (high $24.96B, low $22.02B), average EBITDA is $11.07B (high $11.76B, low $10.37B), average net income is $5.47B (high $5.9B, low $5.05B), average SG&A $3.12B (high $3.31B, low $2.92B), and average EPS is $8.44 (high $9.09, low $7.78). GMAB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $28.87B (high $30.59B, low $27.14B), average EBITDA is $13.6B (high $14.41B, low $12.78B), average net income is $10.93B (high $11.78B, low $10.08B), average SG&A $3.83B (high $4.06B, low $3.6B), and average EPS is $16.85 (high $18.15, low $15.53).

Did the GMAB's actual financial results beat the analysts' financial forecasts?

Based on Genmab's last annual report (Dec 2022), the company's revenue was $14.6B, beating the average analysts forecast of $13.27B by 10.02%. Apple's EBITDA was $7.04B, missing the average prediction of $8.51B by -17.28%. The company's net income was $5.52B, missing the average estimation of $10.47B by -47.27%. Apple's SG&A was $2.68B, missing the average forecast of $3.41B by -21.60%. Lastly, the company's EPS was $8.45, beating the average prediction of $5.92 by 42.75%. In terms of the last quarterly report (Mar 2023), Genmab's revenue was $2.85B, beating the average analysts' forecast of $2.77B by 3.06%. The company's EBITDA was $629M, missing the average prediction of $1.3B by -51.79%. Genmab's net income was $226M, missing the average estimation of $5.93B by -96.19%. The company's SG&A was $676M, beating the average forecast of $367.68M by 83.85%. Lastly, the company's EPS was $0.35, missing the average prediction of $0.642 by -45.50%